Marker Therapeutics (Nasdaq:MRKR) shares closed Wednesday down 25% to $2.93. The company announced in its earnings release that its planned Phase 2 trial of Marker AML in post-allogeneic hematopoietic stem cell transplant patients with acute myeloid leukemia, has been placed on clinical hold in both the adjuvant and active disease setting until response to manufacturing questions from the FDA have been made. The company also noted it will be suspending its Phase 2 trial of TPIV200 in patients with platinum-sensitive advanced ovarian cancer due to insufficient efficacy.
GlaxoSmithKline plc (NYSE: GSK) announced that its Phase 3 trial of Nucala (mepolizumab) in the treatment of patients living with Hypereosinophilic Syndrome (HES), met its primary endpoint, demonstrating a statistically significant result with 50% fewer patients experiencing a HES flare when treated with mepolizumab, compared to placebo (56% vs 28%; p=0.002).
Clovis Oncology, Inc. (NASDAQ:CLVS) announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Shares closed up 20% to $6.55.
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) shares closed down 53% to $0.25 on news of a public offering of 11,428,572 shares together with accompanying common warrants, at a public offering price of $0.35 per share and associated warrants for gross proceeds of $4m.
Lipocine Inc. (NASDAQ:LPCN) also announced a public offering of units consisting of shares of its common stock and warrants to purchase its common stock. Shares, which closed down 13% during normal hours, fell a further 23% to $0.53 after hours.
Kadmon Holdings, Inc. (NYSE:KDMN) announced after hours its intention to offer and sell shares of its common stock in a public offering. Shares closed down 8% after hours to $3.27.
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares closed down 25% after hours to $0.20 on news that it also has commenced a proposed public offering of shares of its common stock.
Therapix Biosciences Ltd. (Nasdaq: TRPX) shares closed up 19% to $1.72. The company announced its single-arm, open-label, Phase 2 trial of THX-110 in patients with obstructive sleep apnea (OSA), met the primary endpoint of the trial.
-
Major price movers (stocks priced > $1.00, volume > 50k):
Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume
ADVANCERS:
IDEAYA Biosciences, Inc. (IDYA): $8.50; +47%.
Mersana Therapeutics, Inc. (MRSN): $2.78; +21%.
Caladrius Biosciences, Inc. (CLBS): $2.67; +18%.
AC Immune SA (ACIU): $6.53; +17%.
Kazia Therapeutics Limited (KZIA): $3.30; +15%.
DECLINERS:
Melinta Therapeutics, Inc. (MLNT): $1.36; -32%.
Replimune Group, Inc. (REPL): $13.61; -19%.
Molecular Templates, Inc. (MTEM): $7.18; -18%.
Viela Bio, Inc. (VIE): $28.08; -13%.
Neon Therapeutics, Inc. (NTGN): $1.65; -12%.
Pipeline updates below:
View in browser »